XML 57 R41.htm IDEA: XBRL DOCUMENT v3.26.1
Segments (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Segments            
Number of operating segments         1  
Number of reportable segments         1  
Stock-based compensation         $ 5,259 $ 2,507
Total segment expense $ 19,297   $ 10,260   34,174 20,182
Net loss 17,959 $ 13,692 7,998 $ (15,193) 31,651 (7,195)
Single Reportable Segment            
Segments            
Compensation and benefits, excluding stock-based compensation 3,147   2,144   6,174 4,383
Stock-based compensation 2,609   1,256   5,259 2,507
Drug manufacturing 2,441   1,850   2,872 3,680
Clinical trial 5,410   2,135   10,453 4,062
Outside general and administrative 906   848   2,150 1,794
Facilities and insurance 630   504   1,188 1,284
Other segment items 4,154   1,523   6,078 2,472
Total segment expense 19,297   10,260   34,174 20,182
Non-operating income, net (1,338)   (2,262)   (2,523) (27,377)
Net loss $ 17,959   $ 7,998   $ 31,651 $ (7,195)